Vendor comparison · 2026
FOXO4-DRI vendors: 4 compared on COAs and price
OtherAlso known as FOXO4 D-Retro-Inverso, Proxofim
Evidence tier
Limited published literature
22 publications over 9 years · trials not yet curated
- Vendors carrying it
- 4
- 4 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- $14.00
- peer median $22.50
- Publications located
- 22
- researched since 2017
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a FOXO4-DRI certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. The lowest listed price is $14.00 per mg at Good Science Bio, against a peer median of $22.50. 4 vendors carrying FOXO4-DRI are compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying FOXO4-DRI
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Simple Peptide | 83.192% | $18.00 (80%) | 0 | — | — | — | — | no reportVisit site |
| 2 | Good Science Bio | 74.571% | $14.00 (62%) | 0 | — | — | — | — | no reportVisit site |
| 3 | BioLongevity Labs | 63.172% | $27.50 (122%) | 0 | — | — | — | — | no reportVisit site |
| 4 | Biotech Peptides | 58.160% | $27.00 (120%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of FOXO4-DRI is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for FOXO4-DRI names a laboratory this index could identify.
Every certificate record
No certificate record for FOXO4-DRI is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2017 — 9 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
22 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
4 of 4 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is FOXO4-DRI?
A synthetic peptide studied as a senolytic — a compound aimed at clearing senescent cells — in preclinical ageing models.
Studied in published research for clearance of senescent cells (senolytic research).
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Published work is preclinical, in cell and animal models of ageing. PepIndex does not evaluate clinical significance and does not describe administration.
- Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression — Circulation (2023)
Peer-reviewed article indexed in PubMed, published in Circulation (2023).
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes — Frontiers in bioengineering and biotechnology (2021)
Peer-reviewed article indexed in PubMed, published in Frontiers in bioengineering and biotechnology (2021).
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI — Nature communications (2025)
Peer-reviewed article indexed in PubMed, published in Nature communications (2025).
- Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline — Naunyn-Schmiedeberg's archives of pharmacology (2026)
Peer-reviewed article indexed in PubMed, published in Naunyn-Schmiedeberg's archives of pharmacology (2026).
- FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway — Frontiers in bioengineering and biotechnology (2025)
Peer-reviewed article indexed in PubMed, published in Frontiers in bioengineering and biotechnology (2025).
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation — Communications biology (2025)
Peer-reviewed article indexed in PubMed, published in Communications biology (2025).
- FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells — Experimental gerontology (2024)
Peer-reviewed article indexed in PubMed, published in Experimental gerontology (2024).
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice — Aging (2020)
Peer-reviewed article indexed in PubMed, published in Aging (2020).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.